Published in Obesity and Diabetes Week, April 24th, 2006
This study is designed to generate the type of safety and efficacy data that could form the basis of a new drug application (NDA).
The 30-week open-label, noninferiority study will assess whether once-weekly exenatide LAR is at least as effective in improving glucose control as twice-daily BYETTA....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week